Title of the pitching session:
AI-driven breakthroughs from target to therapy
Pitching session summary
This pitching session brings together startups leveraging artificial intelligence, digital twins and engineered biologics to transform drug development. Spanning the full value chain from target identification to therapeutic design and clinical acceleration, their platforms enhance speed, precision and scalability. Covering AI-driven target discovery, immunogenicity prediction, antibody engineering, phage therapies and applications in oncology and aging, the session highlights how integrated digital and biological approaches are reshaping healthcare.
Date, time and room information
Monday, May 4, 14:30 - 15:15, room Delhi
Moderation
| Name | Position | Institution |
|---|---|---|
| Annamaria Kauzlaric | Head of digital and health technologies chapter | Swiss Biotech Association |
Pitching companies
| Company name | Pitcher | Title of presentation | Link to company website |
|---|---|---|---|
| TwinEdge Bioscience | Kevin Buyens, PhD, CBO and co-founder | Digital Twins Transforming Drug Development | https://twinedgebio.com/ |
| Lemna Bio | Moustafa Houmani, Co-founder & CEO | Structural AI for Intracellular Targets: From Nomination to Validation | https://www.lemna.bio/ |
| Fy Cappa Biologics | Chiara Rodella, PhD, Project Manager & Business Development | Programmable Fc Engineering for Next-Generation Antibodies | |
| ALP AI | Dr. Christian Vahlensieck, CEO | It Takes One Immune Response to Kill a Drug: Rethinking Immunogenicity in Antibody Development | https://alpbio.ai/ |
| Glass Medical AI | Isabell von Loga, co-founder & COO | Accelerating oncology development using the power of AI | https://www.glassmedical.ai/ |
| Precise Health | José Bila, CEO | AI-Driven Phage Tharapy Platform - Fast, Scalable and Affordable | https://precisehealth.io/ |
| SYDRA | Alexander Dakhovnik, PhD, Founder & CEO/CSO | From AI-Discovered Geroprotectors to Drug Candidates: A Hit-to-Target Approach | https://sydra.bio/ |
Jury members
| Name | Position | Institution |
|---|---|---|
| Philippe Menu | Chief Medical Officer & Chief Product Officer | SOPHiA GENETICS |
| Sandra von Meier | Head of Business Development Life Science | Terra Quantum |
| Maria Escala-Garcia | Investment Associate | Vi Partners |
Swiss Biotech Association
